Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock

Lantern Pharma Inc LTRN announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve survival in animals models of glioblastoma (GBM).
LP-184 treatment induced tumor regression evidenced by greater than 106% tumor growth inhibition in two subcutaneous xenograft models of GBM (U87 and M1123).
LP-184 also prolonged survival in mice bearing an intracranially implanted tumor model of GBM (U87) compared with those that did not receive any drug substance.
Intravenous administration of LP-184 over two cycles reduced subcutaneous xenograft tumor volume in mice by greater than 85% within the treatment group.
Lantern expects to further refine the dosing regimen and cycle in the next phase of work, hoping that additional improvements in survival can be translated into human clinical trials.
LTRN stock has lost 21.70% in the last month.
Price Action: LTRN shares are down 5.56% at $11.04 during the market session on the last check Thursday.